Biofilms can form on living or inert surfaces and prevail in natural, industrial, and hospital environments. They are made of bacteria organized in a coordinated functional community. Biofilms do not respond to antibiotic treatment due to multiple mechanisms of tolerance and resistance. If bacteria are coordinated in a biofilm form, they are significantly less susceptible to antibiotics, thus making the therapeutic approach difficult. The possibility of using drugs aimed at inhibiting the formation of biofilms in combination with current antibiotics is a therapeutic approach with a major potential for this type of persistent bacterial infection. This bibliographic study aims to present the main compounds that act by inhibiting or destroying the bacterial biofilm.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Bryers JD. Medical biofilms. Biotechnology and Bioengineering. 2008;100:1-18.
2. Michel V Doi Y Hellwich K et al. Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). Pure and Applied Chemistry. 2012;8:377-410.
3. Hall-Stoodley L Costerton JW Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nature Reviews Microbiology. 2004;2:95-108.
4. Wu H Moser C Wang HZ et al. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;23;7:1-7.
5. Auler ME Morreira D Rodrigues FF et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Medical Mycology. 2009;48:211-216.
6. Ciofu O Rojo-Molinero E Macià MD et al. Antibiotic treatment of biofilm infections. APMIS. 2017;125:304-319.
7. Rabin N Zheng Y Opoku-Temeng C et al. Agents that inhibit bacterial biofilm formation. Future Med Chem. 2015;7:647-671.
8. Worlitzsch D Tarran R Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317-325.
9. Jensen PO Briales A Brochmann RP et al. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. Pathog Dis. 2014;70:440-443.
10. Cao B Christophersen L Thomsen K et al. Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model. J Antimicrob Chemother. 2015;70:2057-2063.
11. Kadurugamuwa JL Sin L Albert E et al. Direct continuous method for monitoring biofilm infection in a mouse model. Infect Immun. 2003;71:882-890.
12. Rupp ME Ulphani JS Fey PD et al. Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Infect Immun. 1999;67:2627-2632.
13. Hirano L Bayer AS. Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother. 1991;35:685-690.
14. Roche ED Renick PJ Tetens SP et al. Increasing the presence of biofilm and healing delay in a porcine model of MRSA-infected wounds. Wound Repair Regen. 2012;20:537-543.
15. Johansen HK Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun. 2005;73:2504-2514.
16. de Lima Pimenta A Chiaradia-Delatorre LD Mascarello A et al. Synthetic organic compounds with potential for bacterial biofilm inhibition a path for the identification of compounds interfering with quorum sensing. Int J Antimicrob Agents. 2013;42:519-523.
17. Balaban N Cirioni O Giacometti A et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother. 2007;51:2226-2229.
18. Francolini I Norris P Piozzi A et al. Usnic acid a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother. 2004;48:4360-4365.
19. Rasamiravaka T Labtani Q Duez P et al. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. Biomed Res Int. 2015:759348.
20. Rasmussen TB Skindersoe ME Bjarnsholt T et al. Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology. 2005;151:1325-1340.
21. Roy V Meyer MT Smith JA et al. AI-2 analogs and antibiotics: a synergistic approach to reduce bacterial biofilms. Appl Microbiol Biotechnol. 2013;97:2627-2638.
22. Brackman G Cos P Maes L et al. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother. 2001;55:2655-2661.
23. Zeng X Liu X Bian J et al. Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011;55:3015-3017.
24. Jakobsen TH van Gennip M Phipps RK et al. Ajoene a sulfur-rich molecule from garlic inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother. 2012;56:2314-2325.
25. Yang JY Della-Fera MA Nelson-Dooley C et al. Molecular mechanisms of apoptosis induced by ajoene in 3T3-L1 adipocytes. Obesity. 2006;14:388-397.
26. Jakobsen TH Warming AN Vejborg RM et al. A broad range quorum sensing inhibitor working through sRNA inhibition. Sci Rep. 2017;7:9857.
27. Rendueles O Kaplan JB Ghigo JM. Antibiofilm polysaccharides. Environmental Microbiol. 2013;15:334-346.
28. Roy R Tiwari M Donelli G et al. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9:522-554.
29. Durig A Kouskoumvekaki I Vejborg RM et al. Chemoinformatics-assisted development of new anti-biofilm compounds. Applied Microbiol Biotechnol. 2010;87:309-317.
30. Ojha AK Baughn AD Sambandan D et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008;69:164-174.
31. Artini M Romano C Manzoli L et al. Staphylococcal IgM ELISA for the detection of periprosthetic joint infections. J Clin Microbiol. 2011;49:423-425.